Clinical trial
Liposomal Doxorubicin in Treating Patients With Prostate Cancer
NCT00004014 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004014 |
|---|---|
| Title | Liposomal Doxorubicin in Treating Patients With Prostate Cancer |
| Official title | Liposome-Encapsulated Doxorubicin (LED) in Hormone Refractory Prostate Carcinoma, Phase II |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | pegylated liposomal doxorubicin hydrochloride |
| Enrollment | 10 |
| Start date | Apr 1, 1999 |
| Primary completion | Jan 1, 2000 |
| Completion | Nov 1, 2001 |
| First posted | Sep 14, 2004 |
| Last update posted | Aug 16, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: